Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 14/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13840804 | 1.00 | ADRB2 (0.61) | ADRB2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL3922037 | 0.89 | ADRB2 (0.59) | ADRB2CHRM3 | |
| SCHEMBL13840798 | 0.88 | ADRB2 (0.64) | ADRB2CHRM3 | |
| SCHEMBL3923181 | 0.88 | ADRB2 (0.64) | ADRB2CHRM3 | |
| SCHEMBL13840727 | 0.88 | ADRB2 (0.64) | ADRB2MEN1KMT2ACHRM3 | |
| SCHEMBL3915158 | 0.88 | ADRB2 (0.64) | ADRB2MEN1KMT2ACHRM3 | |
| SCHEMBL3917030 | 0.87 | ADRB2 (0.75) | ADRB2CHRM3 | |
| SCHEMBL13840728 | 0.87 | ADRB2 (0.75) | ADRB2CHRM3 | |
| SCHEMBL3924136 | 0.86 | ADRB2 (0.61) | ADRB2CHRM3 | |
| SCHEMBL13840751 | 0.86 | ADRB2 (0.66) | ADRB2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730141-B1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2009-05-27 | — | — | EP | claimed |
| EP-1730141-B1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2009-05-27 | — | — | EP | disclosed |
| US-7538141-B2 | Compounds for the treatment of diseases | PFIZER INC. | 2009-05-26 | — | — | US | disclosed |
| EP-1730141-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | Pfizer Limited (GB) | 2006-12-13 | — | — | EP | disclosed |
| US-20050222128-A1 | Compounds for the treatment of diseases | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
| WO-2005092887-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222128-A1 | Compounds for the treatment of diseases | LTC4S, LTB4R2, CYP11B2 | ADRB2 639/4885MEN1 975/4885NPC1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.